Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zonisamide for Dyskinesias in Parkinson's Disease
NCT03034538Phase 4Suspended
- Sponsor
- Cooper University Health Care
- Start
- Apr 2016
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of zonisamide in dyskinesia (2 arms), sponsored by Cooper University Health Care. Primary endpoints: Tolerability at 12 weeks and Unified Dyskinesia Rating Scale at 12 weeks. Started Apr 2016; status: suspended.
02
Drugs
zonisamide
03
Conditions
dyskinesia
Beyond the preview
Go deeper on NCT03034538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03034538.